You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康方生物-B超7%創13個月新高 機構指公司開坦尼商業化進展順利
格隆匯 01-03 10:41
格隆匯1月3日丨康方生物-B(9926.HK)快速拉昇漲超7%,現報46.25港元創13個月新高價,暫成交2.37億港元,總市值388億港元。第一上海最新報吿稱,維持康方生物-B“買入”評級,考慮處於關鍵性/三期臨牀或已獲批上市的5個產品AK112、AK104(已獲批)、AK105(已獲批)、AK102、AK101風險調整後銷售收入,測算得出合理估值為409億港元,目標價50.05港元。公司開坦尼商業化進展順利,安尼可銷售穩步增長。此外,開坦尼具備參與2022年國家醫保談判目錄調整的條件,若順利通過談判進入醫保,則有望加速進院,銷售放量可期。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account